Abaloparatide and the spine: A narrative review

Jeremy C. Thompson, Nathan Wanderman, Paul A. Anderson, Brett A. Freedman

Research output: Contribution to journalReview articlepeer-review


Osteoporosis is a common and debilitating condition characterized by diminished bone mass and architecture leading to bone fragility. Antiresorptive medicines like bisphosphonates (and less commonly denosumab) are the typical first-line agents for the medical treatment of osteoporosis. However, newer anabolic agents have been shown to improve bone mass and architecture, as well as reduce fracture risk, to a greater degree than traditional antiresorptive therapies. Teriparatide (human recombinant parathyroid hormone (PTH) 1–34, Forteo, Ely Lilly, Indianapolis, IN), which was the first in class to be approved in the United States, is the most widely used anabolic osteoporosis medicine and has shown significant benefit over traditional antiresorptive therapies. However, abaloparatide (synthetic parathyroid-related peptide (PTHrP), Tymlos, Radius Health, Waltham, MA), the second drug in this family, has recently become available for use. In this narrative review, we review the mechanism, effects, and benefits of abaloparatide compared to alternative treatments as well as discuss the current literature in regard to its effect on osteoporosis-related complications in the spine.

Original languageEnglish (US)
Pages (from-to)1023-1033
Number of pages11
JournalClinical interventions in aging
StatePublished - 2020


  • Abaloparatide
  • Anabolic
  • Osteoporosis
  • Spine
  • Teriparatide
  • Tymlos

ASJC Scopus subject areas

  • Geriatrics and Gerontology


Dive into the research topics of 'Abaloparatide and the spine: A narrative review'. Together they form a unique fingerprint.

Cite this